Ara Chackerian Sees A Promising Future For Investments In The Healthcare Sector

In an interview with Ara Chackerian, he described himself as a dedicated entrepreneur specializing in providing healthcare services and a passionate philanthropist. He spoke openly about his new ventures including support for environmental causes and TMS Health Solutions, a network of depression treatment centers. What drives him daily is his desire to promote and bring awareness for alternative treatments to patients suffering from mental disorders.

Ara Chackerian is co-founder of TMS Health Solutions with a mission of expanding accessibility to outpatient facilities by building more centers. TMS has seven or more new facilities to serve Sacramento and San Francisco, California. Each facility has spacious rooms used for treating patients in a relaxing environment. Ara is making a difference by giving easy access to psychiatric care from licensed and certified professionals.

As an experienced investor, he knows the healthcare sectors and the best products for investment opportunities. Ara Chackerian is an author and publishes this information on Medium. In May 2019, he provided his insight on healthcare stock as long-term investment opportunities. He sees a promising future for investing in the healthcare sector that are safe and healthy in the next two to three years. He bases his forecast on recent data revealing the industry makes up approximately 18 percent of the economy in the United States.

Ara Chackerian expects the sector will continue to increase and bring investment opportunities to investors. The companies an investor should keep the eyes on are pharmaceutical and biotechnology. They are safe with expectations of substantial growth regardless of the conditions of the economy. The stocks attracting investors are those aligned with retailers including Walgreens and CVS, for an example. Chackerian observed the financial performance of healthcare stock is stronger while partnerships has the prospect of becoming future mergers and bring visibility of healthcare products.

Marc Beer, Chairperson, CEO and Co-Founder of Renovia Inc

Marc Beer has more than 25 years of commercialization and development experience in the field of pharmaceuticals, devices, biotechnology, and diagnostics. He founded Renovia Company together with Ramon Iglesias, Yolanda Lorie and MD in the year 2016. The company successfully closed its series of financing with the topmost healthcare venture funds. In the year 200, Mark Beer became the Chief Executive Officer of the ViaCell. The company is a biotechnology firm that specializes in the development, preservation and the collection of the umbilical cord blood stem cell.

 

For the past seven years, he has led the firm from its inception to a robust and rapidly growing commercial company. Under his leadership as the CEO, the organization went public in the year 2005 and grew with over 300 employees. In addition to serving as the Chief Executive Officer of the company, he also served as a member of the biopharmaceutical organization and the board of directors of the Erytech Pharma.

 

Marc Beer is a graduate of Miami University, Oxford, OH. In his career, he held various career positions within a specialty care firm that is committed to improving treatments of the debilitating body issues that are difficult to treat and diagnose. The most recent position that he has held is the deputy president of the Global Marketing where Marc Beer was responsible for the launch of various firm products. Its main objective was to address the rare disease populations on the world scale. He was also the founding Chairperson of the board of directors and the compensation board of Good Start Genetics.

 

Marc Beer’s Support for the Women Health Startup

 

Marc Beer recently raised approximately $42M to fund and support the women’s startup Renovia Inc. The organization offers therapeutic and diagnostic devices for the treatment of various pelvic floor disorders. This funding will help in the development and the testing of four major new products. The organization is developing multiple therapeutic and diagnostic products to treat diseases such as urinary incontinence that will help over 250 million women in the world.

 

The Longwood support which is a healthcare-centered investment firm that had earlier invested in Renovia, collaborated with the Series B Round to develop and test for diagnostic products which include the current generation of the Leva product. During the funding, Mark Beer said that the organization is excited to have the full support of the company financiers of the organization. He also said that the investors are willing to share the vision of the organization to treat, diagnose and improve the lives of millions of women in the world. Learn more : https://www.slideshare.net/MarcBeer

Copyright The Changes Seekers 2019
Tech Nerd theme designed by FixedWidget